152 related articles for article (PubMed ID: 38824632)
1. US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
Rucker JA; Beinfeld MT; Enright DE; Germack HD; Panjabi S; Chakinala MM; Chambers JD
J Manag Care Spec Pharm; 2024 Jun; 30(6):541-548. PubMed ID: 38824632
[TBL] [Abstract][Full Text] [Related]
2. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease.
Margaretos NM; Panzer AD; Lai RC; Sanon M; Michalopoulos E; Redmond AM; Moghadam R; Chambers JD
J Manag Care Spec Pharm; 2021 Sep; 27(9):1221-1229. PubMed ID: 34464213
[No Abstract] [Full Text] [Related]
3. Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
Jenkins NB; Rucker JA; Klimchak AC; Sedita LE; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):472-479. PubMed ID: 36864544
[No Abstract] [Full Text] [Related]
4. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Panzer AD; Ingham M; Martin S; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
[No Abstract] [Full Text] [Related]
5. Specialty drug coverage varies between health plans' medical and pharmacy benefit policies.
Levine AA; Panzer AD; Kauf TL; O'Sullivan AK; Strand L; Chambers JD
J Manag Care Spec Pharm; 2023 Jun; 29(6):607-613. PubMed ID: 37276044
[No Abstract] [Full Text] [Related]
6. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
[No Abstract] [Full Text] [Related]
7. Use of prescriber requirements among US commercial health plans.
Lenahan K; Panzer AD; Gertler R; Chambers JD
J Manag Care Spec Pharm; 2021 Dec; 27(12):1757-1762. PubMed ID: 34818091
[No Abstract] [Full Text] [Related]
8. Variation in access to hemophilia A treatments in the United States.
Margaretos NM; Patel AM; Panzer AD; Lai RC; Whiteley J; Chambers JD
J Med Econ; 2021; 24(1):1143-1148. PubMed ID: 34538215
[TBL] [Abstract][Full Text] [Related]
9. Characterizing health plan evidence review practices.
Panzer AD; Enright DE; Graff J; Chambers JD
J Manag Care Spec Pharm; 2022 Sep; 28(9):1053-1058. PubMed ID: 36001106
[No Abstract] [Full Text] [Related]
10. Patients' access to rare neuromuscular disease therapies varies across US private insurers.
Margaretos NM; Bawa K; Engmann NJ; Chambers JD
Orphanet J Rare Dis; 2022 Feb; 17(1):36. PubMed ID: 35123543
[TBL] [Abstract][Full Text] [Related]
11. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
Robinson SW; Brantley K; Liow C; Teagarden JR
J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
[TBL] [Abstract][Full Text] [Related]
12. Commercial coverage of specialty drugs, 2017-2021.
Rucker JA; Beinfeld MT; Jenkins NB; Enright DE; Henderson RR; Chambers JD
Health Aff Sch; 2023 Aug; 1(2):qxad030. PubMed ID: 38756241
[TBL] [Abstract][Full Text] [Related]
13. Variation in Medicaid and commercial coverage of cell and gene therapies.
Beinfeld MT; Rucker JA; Jenkins NB; de Breed LA; Chambers JD
Health Policy Open; 2023 Dec; 5():100103. PubMed ID: 38023441
[TBL] [Abstract][Full Text] [Related]
14. Limited role of patient input in specialty drug coverage policies.
D'Cruz B; Graff JS; Panzer AD; Chambers JD
J Manag Care Spec Pharm; 2021 Aug; 27(8):1067-1076. PubMed ID: 34337996
[No Abstract] [Full Text] [Related]
15. What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?
Panzer AD; Margaretos NM; Lai RC; Enright DE; Chambers JD
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1307-1311. PubMed ID: 32212282
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
19. Varied use of step therapy among Medicare Advantage plans.
Jenkins NB; Nichols DE; Enright DE; Chambers JD
Am J Manag Care; 2023 Sep; 29(9):464-468. PubMed ID: 37729529
[TBL] [Abstract][Full Text] [Related]
20. Advances in targeted therapy for pulmonary arterial hypertension in children.
Li L; Zhu X; Chen X; Gao J; Ding C; Zhang M; Ma S
Eur J Pediatr; 2023 May; 182(5):2067-2076. PubMed ID: 36527480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
